These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 1985785)
1. Successful treatment of murine melanoma with bryostatin 1. Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Hornung RL; Pearson JW; Beckwith M; Longo DL Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368 [TBL] [Abstract][Full Text] [Related]
3. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857 [TBL] [Abstract][Full Text] [Related]
4. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041 [TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595 [TBL] [Abstract][Full Text] [Related]
7. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041 [TBL] [Abstract][Full Text] [Related]
8. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium. Kraft AS; Adler V; Hall P; Pettit GR; Benjamin WH; Briles DE Cancer Res; 1992 Apr; 52(8):2143-7. PubMed ID: 1559218 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo. La Porta CA; Di Dio A; Porro D; Comolli R Melanoma Res; 2000 Apr; 10(2):93-102. PubMed ID: 10803709 [TBL] [Abstract][Full Text] [Related]
10. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Basu A; Lazo JS Cancer Res; 1992 Jun; 52(11):3119-24. PubMed ID: 1591725 [TBL] [Abstract][Full Text] [Related]
12. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982 [TBL] [Abstract][Full Text] [Related]
13. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Kalland T Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041 [TBL] [Abstract][Full Text] [Related]
14. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449 [TBL] [Abstract][Full Text] [Related]
15. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900 [TBL] [Abstract][Full Text] [Related]
16. Contrasting duration of inhibition of cell-cell communication in primary mouse epidermal cells by phorbol 12,13-dibutyrate and by bryostatin 1. Pasti G; Rivedal E; Yuspa SH; Herald CL; Pettit GR; Blumberg PM Cancer Res; 1988 Jan; 48(2):447-51. PubMed ID: 3422054 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. Trenn G; Pettit GR; Takayama H; Hu-Li J; Sitkovsky MV J Immunol; 1988 Jan; 140(2):433-9. PubMed ID: 3257237 [TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of bryostatins and phorbol esters on arachidonic acid metabolite release and epidermal growth factor binding in C3H 10T1/2 cells. Dell'Aquila ML; Herald CL; Kamano Y; Pettit GR; Blumberg PM Cancer Res; 1988 Jul; 48(13):3702-8. PubMed ID: 3132318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]